DHP — Competitive Intelligence Brief

DHP (DHP) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: calcium channel blocker. Area: Cardiovascular.

marketed calcium channel blocker L-type calcium channels Cardiovascular Small molecule

Target snapshot

DHP (DHP) — Centro de Investigacao em Saude de Manhica. DHP is a dihydropyridine calcium channel blocker that works by relaxing blood vessels and reducing blood pressure.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
DHP TARGET	DHP	Centro de Investigacao em Saude de Manhica	marketed	calcium channel blocker	L-type calcium channels
Nitrendipine/Atenolol	Nitrendipine/Atenolol	Shanghai Jiao Tong University School of Medicine	marketed	Calcium channel blocker / Beta-blocker combination	L-type calcium channels; Beta-1 adrenergic receptor
Amlodipine, Telmisartan, Amiloride Compound , Simvastatin	Amlodipine, Telmisartan, Amiloride Compound , Simvastatin	Chinese Academy of Medical Sciences, Fuwai Hospital	marketed	Antihypertensive combination (calcium channel blocker + angiotensin II receptor blocker + potassium-sparing diuretic + statin)	L-type calcium channels, AT1 angiotensin II receptor, epithelial sodium channels (ENaC), HMG-CoA reductase
Atorvastatin, Amlodipine, Perindopril	Atorvastatin, Amlodipine, Perindopril	Charles University, Czech Republic	marketed	Fixed-dose combination: statin, calcium channel blocker, ACE inhibitor	HMG-CoA reductase (atorvastatin); L-type calcium channels (amlodipine); Angiotensin-converting enzyme (perindopril)
Amiodarone Pill	Amiodarone Pill	Our Lady of the Lake Hospital	marketed	Class III antiarrhythmic agent	Potassium channels (hERG), sodium channels, L-type calcium channels, beta-adrenergic receptors
Nicardipine , Esmolol	Nicardipine , Esmolol	Nanjing Medical University	marketed	Calcium channel blocker + Beta-1 selective adrenergic antagonist combination	L-type calcium channels; Beta-1 adrenergic receptor
Rate-control therapy	Rate-control therapy	Our Lady of the Lake Hospital	marketed	AV nodal blocking agents (beta-blockers, non-dihydropyridine calcium channel blockers, or cardiac glycosides)	AV nodal conduction (multiple targets depending on agent: beta-1 adrenergic receptors, L-type calcium channels, or adenosine receptors)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (calcium channel blocker class)

1. Assistance Publique - Hôpitaux de Paris · 1 drug in this class
2. CalciMedica, Inc. · 1 drug in this class
3. Centro de Investigacao em Saude de Manhica · 1 drug in this class